In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells

Engineered Fc-lacking bispecific antibodies have shown an exceptionally high potency for recruiting lymphocyte effector cells and enhancing antitumor activity, which is under evaluation in several clinical trials. However, current treatment regimens raise some issues that should be considered, such...

Full description

Saved in:
Bibliographic Details
Published inAntibodies (Basel) Vol. 2; no. 3; pp. 415 - 425
Main Authors Compte, Marta, Nuñez-Prado, Natalia, Sanz, Laura, Alvarez-Vallina, Luis
Format Journal Article Book Review
LanguageEnglish
Published Basel MDPI AG 01.09.2013
Subjects
bispecific antibodies
cell-based therapy
gene therapy
immunotherapeutic neovessels
immunotherapeutic organoids
in vivo secretion
Lymphocytes
Online AccessGet full text

Cover

More Information
Summary:Engineered Fc-lacking bispecific antibodies have shown an exceptionally high potency for recruiting lymphocyte effector cells and enhancing antitumor activity, which is under evaluation in several clinical trials. However, current treatment regimens raise some issues that should be considered, such as the high cost of clinical-grade bispecific antibodies and the achievement of sustained therapeutic plasma levels. The use of gene transfer methods may circumvent problems related to large-scale production and purification, and result in sustained therapeutic plasma concentrations of the Fc-lacking bispecific antibodies. In fact, terminally differentiated cells and non-terminally differentiated cells can be genetically modified to secrete functionally active bispecific antibodies exerting clear anti-tumor effects. This review highlights the relevance of different promising strategies for in vivo delivery of therapeutic bispecific antibodies.
ISSN:2073-4468
2073-4468
DOI:10.3390/antib2030415